TWI318116B - Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents - Google Patents
Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agentsInfo
- Publication number
- TWI318116B TWI318116B TW096138754A TW96138754A TWI318116B TW I318116 B TWI318116 B TW I318116B TW 096138754 A TW096138754 A TW 096138754A TW 96138754 A TW96138754 A TW 96138754A TW I318116 B TWI318116 B TW I318116B
- Authority
- TW
- Taiwan
- Prior art keywords
- prophylaxis
- viral
- treatment
- pharmaceutical compositions
- protease inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13907099P | 1999-06-11 | 1999-06-11 | |
US19021100P | 2000-03-17 | 2000-03-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200804252A TW200804252A (en) | 2008-01-16 |
TWI318116B true TWI318116B (en) | 2009-12-11 |
Family
ID=26836833
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093114799A TWI299000B (en) | 1999-06-11 | 2000-06-08 | Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents |
TW089111145A TW593248B (en) | 1999-06-11 | 2000-06-08 | Inhibitors of aspartyl protease |
TW096138754A TWI318116B (en) | 1999-06-11 | 2000-06-08 | Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093114799A TWI299000B (en) | 1999-06-11 | 2000-06-08 | Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents |
TW089111145A TW593248B (en) | 1999-06-11 | 2000-06-08 | Inhibitors of aspartyl protease |
Country Status (31)
Country | Link |
---|---|
EP (2) | EP1686113B1 (zh) |
JP (2) | JP4503896B2 (zh) |
KR (1) | KR100762188B1 (zh) |
CN (2) | CN101245058A (zh) |
AR (1) | AR031520A1 (zh) |
AT (2) | ATE534622T1 (zh) |
AU (1) | AU779994B2 (zh) |
BR (1) | BR0011745A (zh) |
CA (1) | CA2380858C (zh) |
CO (1) | CO5160337A1 (zh) |
CY (1) | CY1112632T1 (zh) |
CZ (1) | CZ303052B6 (zh) |
DE (1) | DE60027722T2 (zh) |
DK (2) | DK1686113T3 (zh) |
ES (2) | ES2263478T3 (zh) |
HK (1) | HK1046899B (zh) |
HU (1) | HUP0300385A3 (zh) |
IL (3) | IL146918A0 (zh) |
MX (1) | MXPA01012808A (zh) |
MY (1) | MY137777A (zh) |
NO (1) | NO323951B1 (zh) |
NZ (1) | NZ516003A (zh) |
PE (1) | PE20010230A1 (zh) |
PL (1) | PL210227B1 (zh) |
PT (2) | PT1686113E (zh) |
SI (1) | SI1194404T1 (zh) |
TN (1) | TNSN00129A1 (zh) |
TR (3) | TR200202528T2 (zh) |
TW (3) | TWI299000B (zh) |
WO (1) | WO2000076961A1 (zh) |
ZA (1) | ZA200110177B (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999065870A2 (en) | 1998-06-19 | 1999-12-23 | Vertex Pharmaceuticals Incorporated | Sulfonamide inhibitors of aspartyl protease |
AR031520A1 (es) * | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
ES2275866T3 (es) | 2001-02-14 | 2007-06-16 | Tibotec Pharmaceuticals Ltd. | 2-(aminosustituido)-benzotiazol-sulfonamidas de amplio esprecto inhibidoras de la proteasa de vih. |
US7285566B2 (en) * | 2002-01-07 | 2007-10-23 | Erickson John W | Resistance-repellent retroviral protease inhibitors |
MY142238A (en) | 2002-03-12 | 2010-11-15 | Tibotec Pharm Ltd | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors |
EA200401437A1 (ru) * | 2002-04-26 | 2005-04-28 | Джилид Сайэнс, Инк. | Ненуклеозидные ингибиторы обратной транскриптазы для лечения вич инфекции, способ их получения (варианты), способ увеличения периода полупревращения ненуклеозидного соединения, обладающего активностью против ретровирусов, и способ получения фармацевтической композиции, обладающей специфичностью к лейкоцитам |
US6632816B1 (en) * | 2002-12-23 | 2003-10-14 | Pharmacor Inc. | Aromatic derivatives as HIV aspartyl protease inhibitors |
WO2005000249A2 (en) * | 2003-06-27 | 2005-01-06 | Smithkline Beecham Corporation | Preparation of chemical compounds |
JP5043429B2 (ja) | 2003-08-18 | 2012-10-10 | ハー・ルンドベック・アクチエゼルスカベット | トランス−4−((1r,3s)−6−クロロ−3−フェニルインダン−1−イル)−1,2,2−トリメチルピペラジンのコハク酸塩およびマロン酸塩、および薬剤としての使用方法 |
JP5020638B2 (ja) * | 2003-12-15 | 2012-09-05 | シェーリング コーポレイション | 複素環式アスパルチルプロテアーゼインヒビター |
JP2007528423A (ja) | 2004-03-11 | 2007-10-11 | セコイア、ファーマシューティカルズ、インコーポレイテッド | 耐性防止レトロウイルスプロテアーゼ阻害薬 |
TWI383975B (zh) | 2004-03-31 | 2013-02-01 | Tibotec Pharm Ltd | 製備(3R,3aS,6aR)六氫-呋喃并〔2,3-b〕呋喃-3-醇之方法 |
US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
TWI453198B (zh) | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
TWI376373B (en) | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
WO2006104646A1 (en) * | 2005-03-11 | 2006-10-05 | Smithkline Beecham Corporation | Hiv protease inhibitors |
AU2006319716B2 (en) | 2005-11-30 | 2012-02-02 | Taimed Biologics, Inc. | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation |
EP2069356A1 (en) * | 2006-07-24 | 2009-06-17 | Gilead Sciences, Inc. | Bisfuranyl protease inhibitors |
DE602007012365D1 (de) | 2006-11-09 | 2011-03-17 | Little Island Co Cork | Verfahren zur herstellung von hexahydrofuroä2,3-büfuran-3-ol |
EP2120562A4 (en) * | 2006-11-21 | 2010-01-13 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS |
DE602008005012D1 (de) | 2007-04-27 | 2011-03-31 | Little Island Co Cork | Herstellungsverfahren für n-isobutyl-n-(2-hydroxy-rivate |
GB2452952A (en) * | 2007-09-20 | 2009-03-25 | Npil Pharmaceuticals | N-[2-Hydroxy-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-sulphonamide derivatives via N-[2-oxo-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-imine skeleton |
US8592487B2 (en) | 2007-10-26 | 2013-11-26 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
AU2010299959B2 (en) * | 2009-09-22 | 2016-07-21 | Tibotec Pharmaceuticals | Treatment and prevention of HIV infection |
WO2011061590A1 (en) | 2009-11-17 | 2011-05-26 | Hetero Research Foundation | Novel carboxamide derivatives as hiv inhibitors |
CN103193570B (zh) * | 2013-04-09 | 2014-01-22 | 湖北来凤腾升香料化工有限公司 | 一种羟基高选择性保护方法 |
EP3192794A4 (en) * | 2014-09-11 | 2018-06-27 | Shionogi & Co., Ltd. | Sustained hiv protease inhibitor |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3635907A1 (de) * | 1986-10-22 | 1988-04-28 | Merck Patent Gmbh | Hydroxy-aminosaeurederivate |
CA2032259A1 (en) * | 1989-12-18 | 1991-06-19 | Wayne J. Thompson | Hiv protease inhibitors useful for the treatment of aids |
US5475013A (en) * | 1990-11-19 | 1995-12-12 | Monsanto Company | Retroviral protease inhibitors |
WO1992008701A1 (en) * | 1990-11-19 | 1992-05-29 | Monsanto Company | Retroviral protease inhibitors |
US5843946A (en) * | 1992-08-25 | 1998-12-01 | G.D. Searle & Co. | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
DK0885881T3 (da) * | 1992-10-30 | 2003-07-14 | Searle & Co | Sulfonylalkanoylaminohydroxyethylaminosulfaminsyrer, der er anvendelige som retrovirale proteaseinhibitorer |
ES2127938T3 (es) * | 1993-08-24 | 1999-05-01 | Searle & Co | Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas. |
ES2303337T3 (es) * | 1995-01-20 | 2008-08-01 | G.D. Searle Llc | Inhibidores de la proteasa retroviral de bis-hidroxietilamino sulfonamida. |
US5756533A (en) * | 1995-03-10 | 1998-05-26 | G.D. Searle & Co. | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5705500A (en) * | 1995-03-10 | 1998-01-06 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6150556A (en) * | 1995-03-10 | 2000-11-21 | G. D. Dearle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
CZ297676B6 (cs) * | 1995-03-10 | 2007-03-07 | G. D. Searle & Co. | Deriváty hydroxyethylaminosulfonamidu jako inhibitory retrovirové proteázy, farmaceutická kompozice |
US5691372A (en) * | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
AU7722296A (en) * | 1995-11-15 | 1997-06-05 | G.D. Searle & Co. | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
GB9712504D0 (en) * | 1997-06-17 | 1997-08-20 | Dundee Teaching Hospitals Nhs | Thermal imaging method and apparatus |
WO1999010373A1 (en) * | 1997-08-26 | 1999-03-04 | Wisconsin Alumni Research Foundation | Non-immunosuppressive cyclosporins and their use in the prevention and treatment of hiv infection |
AR031520A1 (es) * | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
-
2000
- 2000-06-07 AR ARP000102852A patent/AR031520A1/es active IP Right Grant
- 2000-06-08 CZ CZ20014431A patent/CZ303052B6/cs not_active IP Right Cessation
- 2000-06-08 PE PE2000000573A patent/PE20010230A1/es not_active Application Discontinuation
- 2000-06-08 DE DE60027722T patent/DE60027722T2/de not_active Expired - Lifetime
- 2000-06-08 AU AU56006/00A patent/AU779994B2/en not_active Ceased
- 2000-06-08 TR TR2002/02528T patent/TR200202528T2/xx unknown
- 2000-06-08 AT AT06009072T patent/ATE534622T1/de active
- 2000-06-08 HU HU0300385A patent/HUP0300385A3/hu unknown
- 2000-06-08 TN TNTNSN00129A patent/TNSN00129A1/fr unknown
- 2000-06-08 EP EP06009072A patent/EP1686113B1/en not_active Expired - Lifetime
- 2000-06-08 JP JP2001503821A patent/JP4503896B2/ja not_active Expired - Fee Related
- 2000-06-08 KR KR1020017016293A patent/KR100762188B1/ko not_active IP Right Cessation
- 2000-06-08 NZ NZ516003A patent/NZ516003A/xx not_active IP Right Cessation
- 2000-06-08 CN CNA2008100096668A patent/CN101245058A/zh active Pending
- 2000-06-08 PT PT06009072T patent/PT1686113E/pt unknown
- 2000-06-08 PT PT00941279T patent/PT1194404E/pt unknown
- 2000-06-08 PL PL352830A patent/PL210227B1/pl not_active IP Right Cessation
- 2000-06-08 DK DK06009072.7T patent/DK1686113T3/da active
- 2000-06-08 DK DK00941279T patent/DK1194404T3/da active
- 2000-06-08 BR BR0011745-5A patent/BR0011745A/pt not_active Application Discontinuation
- 2000-06-08 CO CO00042752A patent/CO5160337A1/es unknown
- 2000-06-08 CA CA2380858A patent/CA2380858C/en not_active Expired - Fee Related
- 2000-06-08 ES ES00941279T patent/ES2263478T3/es not_active Expired - Lifetime
- 2000-06-08 SI SI200030872T patent/SI1194404T1/sl unknown
- 2000-06-08 EP EP00941279A patent/EP1194404B1/en not_active Expired - Lifetime
- 2000-06-08 WO PCT/US2000/015781 patent/WO2000076961A1/en active Application Filing
- 2000-06-08 IL IL14691800A patent/IL146918A0/xx unknown
- 2000-06-08 CN CNB008104395A patent/CN100516034C/zh not_active Expired - Fee Related
- 2000-06-08 TR TR2002/00407T patent/TR200200407T2/xx unknown
- 2000-06-08 TW TW093114799A patent/TWI299000B/zh not_active IP Right Cessation
- 2000-06-08 AT AT00941279T patent/ATE325091T1/de active
- 2000-06-08 MY MYPI20002595A patent/MY137777A/en unknown
- 2000-06-08 ES ES06009072T patent/ES2375823T3/es not_active Expired - Lifetime
- 2000-06-08 TR TR2006/03871T patent/TR200603871T2/xx unknown
- 2000-06-08 TW TW089111145A patent/TW593248B/zh not_active IP Right Cessation
- 2000-06-08 TW TW096138754A patent/TWI318116B/zh not_active IP Right Cessation
- 2000-06-08 MX MXPA01012808A patent/MXPA01012808A/es active IP Right Grant
-
2001
- 2001-12-04 IL IL146918A patent/IL146918A/en not_active IP Right Cessation
- 2001-12-10 NO NO20016034A patent/NO323951B1/no not_active IP Right Cessation
- 2001-12-11 ZA ZA200110177A patent/ZA200110177B/en unknown
-
2002
- 2002-09-23 HK HK02106939.9A patent/HK1046899B/zh not_active IP Right Cessation
-
2008
- 2008-09-08 JP JP2008230351A patent/JP2009046493A/ja not_active Withdrawn
-
2009
- 2009-12-09 IL IL202633A patent/IL202633A/en not_active IP Right Cessation
-
2012
- 2012-02-22 CY CY20121100182T patent/CY1112632T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI318116B (en) | Pharmaceutical compositions for treatment or prophylaxis of viral infections comprising novel aspartyl protease inhibitors and additional anti-viral agents | |
IL215891A (en) | Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections | |
AU3413100A (en) | Method and compositions for preventing or reducing hiv infection by use of inhibitors for leucine aminopeptidase | |
HU9802525D0 (en) | Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections | |
PL344223A1 (en) | Compositions for the treatment of hiv and other viral infections | |
HUP0401730A3 (en) | Peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them | |
MY151199A (en) | Substituted diphenyl heterocycles useful for treating hcv infection | |
HUP0001170A3 (en) | Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer | |
IL191905A0 (en) | Inhibitors of serine proteases particularly hepatitis c virus ns3 protease, pharmaceutical compositions containing the same and the use thereof | |
HUP0303358A3 (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them | |
HUP0201846A3 (en) | Amonobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them | |
AU1101501A (en) | Methods and compositions for treatment of keratoconus using protease inhibitors | |
PL312908A1 (en) | Drugs for treating aids and/or hiv infections, containing composition consisting of quinoxalin and protease inhibitors | |
WO2002085358A3 (en) | Antiviral agents and methods of treating viral infections | |
AU3719100A (en) | Inhibitors of serine protease activity, methods and compositions for treatment of viral infections | |
HUP0500164A3 (en) | Heterocyclic substituted benzenesulfonamides as hiv protease inhibitors and pharmaceutical compositions containing them | |
AU2002325169A1 (en) | Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases | |
WO2002000613A3 (en) | Inhibitors of hepatitis b virus infection | |
IL107755A0 (en) | Pharmacuetical compositions for the treatment and prophylaxis of parasitic infections | |
HK1041444A1 (zh) | 用於治療hiv感染的包含peg-天冬酰胺酶的藥物組合物 | |
SI1173194T1 (en) | Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation | |
HUP0200466A2 (en) | Lipoglycan compositions and methods of treating parasitic infections | |
AU4650500A (en) | Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis | |
AU3524700A (en) | Prevention and treatment of viral infections | |
FI970565A (fi) | HIV-proteaasia inhiboiva yhdistelmä |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |